Skip to content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Paired design study by real-time PCR: miR-378* and miR-145 are potent early diagnostic biomarkers of human colorectal cancer

  • Juan Peng1,
  • Zhengyong Xie2,
  • Liyang Cheng2Email author,
  • Yuxin Zhang2,
  • Junyong Chen2,
  • Hongping Yu1,
  • Zehang Li2 and
  • Huixing Kang2
Contributed equally
BMC Cancer201515:158

https://doi.org/10.1186/s12885-015-1123-2

Received: 27 June 2014

Accepted: 24 February 2015

Published: 21 March 2015

Abstract

Background

Although microRNAs offer great potential as cancer biomarkers, effective clinical dignostics and tumor maker have not been verified to diagnose with colorectal cancer (CRC). The purpose of our study is to systematically assess the expression of miRNAs in matched cancer and normal tissue samples to identify promising diagnostic microRNA (miRNA) biomarkers for CRC.

Methods

In our study, we examined by Real-Time PCR the expression levels of 96 mature miRNA in 32 CRC patients with differently expressed tumors versus normal colon tissues. Using enter and stepwise variable selection methods separately, conditional logistic regression was conducted to identify miRNAs associated with CRC. The classification performance of these indicators was assessed under the Fisher discriminant analysis. Receiver operating characteristic curve analyses were applied to obtain diagnostic utility of the differentially expressed miRNAs.

Results

In this study, we confirmed 11 overexpressed miRNAs with no less than twofold difference, and 85 downexpressed miRNAs with up to 0.5-fold difference in CRC from 96 aberrantly expressed miRNAs being identified by real-time PCR. Conditional logistic regression results confirmed that miRNA-378 and miRNA-145 expression profile was statistically significant. The error diagnosis rate of these two miRNAs are 0.194 and 0.113, separeately, showing by discriminant analysis.

Conclusions

MiRNA-145 and miRNA-378* are potential biomarkers for early detection of CRC, which may help in diagnosing CRC in early period.

Keywords

MiRNAColorectal cancerEarly diagnosis

Background

Colorectal cancer (CRC) yields the second highest mortality rate in China, showing a high incidence trend. Early diagnosis and treatment of CRC is an effective way to improve patients’ survival. However, most cases are diagnosed with CRC at late stages as current clinical diagnostics and tumor markers are inconvenient and population screening rates are low. Therefore, there is an imperative need to search for specific, sensitive biomarkers for the early diagnosis of CRC.

MiRNA is small, non-coding sighle-strand RNA, which contain of about 19 nucleotides to 25 nucleotides arising from one arm of longer endogenous hairpin transcripts. Growing studies suggests that microRNA (miRNA) plays an important role in colon disease process, including cell differention, development, proliferation and translation. Futhermore, misregulation of miRNA expression might contribute to human diseases. Evidence has shown that miRNA can work with the target mRNA 3′ non-transcribed with incomplete or complete pairing and negatively regulate gene expression in post-transcriptional level by degrading the target mRNA or inhibit translation [1].

There is increasing evidence that some miRNAs may be used as diagnostic biomarkers for CRC by identifying differences in miRNA expression of colorectal tumors and ajacent non-neoplastic tissues from patients. For example, E Bandrés et al. reported that miR-31, miR-96, miR-133b, miR-135b, miR-145, and miR-183 are the most significantly deregulated miRNAs and the expression level of miR-31 was correlated with the stage of CRC tumor [2]. Calin et al. reported that one of the most upregulated miRNAs is miR-106a, which is consistently reported in six studies, and the five most downregulated miRNAs are miR-30a-3p, miR-139, miR-145, miR-125a, and miR-133a, which are consistently reported and differentially expressed in four studies; these miRNAs may actually be of clinical use as diagnostic/prognostic biomarkers or therapeutic targets [3]. However, most of the screening studies have small sample with no prediction accuracy of candidate diagnostic biomarkers.

To determine much sensitive indicators, the present study examined the expression of 96 mature miRNAs in a panel of 31 matched pairs of tumoral and non-tumoral tissues by real-time PCR. Conditional logistic regression was used to screen the factors contributed to the occurrence of tumor, among which miR-145 and miR-378* were found being statistically significant. Futher analysis reveals miR-378* and miR-145 exhibits potential as a good diagnostic and prognostic marker.

Methods

To investigate whether miRNAs are differentially expressed in CRC versus normal colon tissues, surgical specimens of cancer tissue and adjacent normal mucosa were obtained from 32 patients with colorectal cancer who underwent surgery at The General Hospital of PLA Guangzhou Military Area between 2012 and 2013. Fresh CRC and adjacent noncancerous colorectal tissues, which were used as specimens, were obtained by experienced surgeons and examined by experienced pathologists. Surgery was performed to remove the primary tumor immediately after carcinoma was diagnosed. Incision was performed from the edge of the site by at least 2 cm. Tumor stage was classified according to the International Union against Cancer (UICC, 6th ed., 2002). Informed written consent was obtained from each patient, and research protocols were approved by the Medical Ethics Committee of the General Hospital of PLA Guangzhou Military Area.

RNA extraction was performed to obtain cryopreserved tissues and adjacent group-woven sliced tissues with liquid nitrogen, grinding into powerder using Trizol total RNA isolation reagent as per the manufacturer’s protocal [4]. Concentration and purity of isolated RNA were assessed by measuring the optical density at 260 (OD260) and 280 nm (OD280).

Isolated RNA was of high purity and integrity. A260/A280 ratios for the human genomic DNA extracted from spit were consistently within generally acceptable values of 1.7 to 2.0 [5]. Reverse transcription-related operations were performed following the kit instructions.

Quantification was performed by real-time PCR using SYBR Premix Ex Taq TM (TaKaRa) for the most upregulated or most downregulated miRNAs. The primers for U6 were obtained from TaKaRa. PCR was performed in a real-time PCR system (Bio-Rad) with the following reaction conditions: Real-time PCR kit was operated in strict accordance with the manufacturer’s instructions. The cycling program consists of 1× at 95°C for 10 min and 40× (15 s at 95°C) at 60°C, plus extension of 60 s, for a total of 40 cycles [6].

Default threshold settings were used as threshold cycle (Ct) data. The Ct is the fractional cycle number at which the fluorescence passes the fixed threshold [7]. After calculating the Ct value, expression values were normalized to those for U6, which were calculated as ΔCt = Ct − CtU6 (expression of the relative expression profile). Therefore, ΔΔCt = ΔCt (tumor group) − ΔCt (control group) [8]. Relative quantification of miRNA expression was calculated with 2-ΔΔCt method, which represents relative fold changes of miRNA expression.

Statistical analysis

The patients’ demographics for continuous variables were reported as mean ± SD, while percentage, and frequency calculated for categorical variables. Paired Student’s t-test was used to determine the level of significance (P < 0.05). Conditional logistic regression model was used to calculate odds ratio with 95% confidence interval to estimate association and control the potential confounding variables, confirming diagnostic use of miRNAs that contributes to CRC probability. Discriminant analysis for classification of tissues types [9] was performed to determine the discriminative ability of the screened miRNAs. Statistical analysis was performed using IBM SPSS version 16.0 software. P values of less than 0.05 were considered statistically significant.

Results

Clinicopathological characteristics of CRC patients

The clinicopathological factors of the 32 (16 women) participants with CRC recruited to the study are showed in Table 1. The mean age of the respondents was 31.3 years (±5.6 SD). No participants showed evidence of disease complications. A total of 23 participants (71.9%) were within the age range of 60 years to 83 years, while9 patients (28.1%) were in the age range of 20 years to 60 years. In addition, 16 participants (50%) had stage II disease, while the other 16 (50%) were diagnosed with stages III and IV disease. Although Beştaş R et al. suggested that vascular endothelial growth factor (VEGF) expression is significantly correlated with advanced stage [10], we did not found any correlation in this study. Among nine patients reported VEGF, 4 patients (44.44%) were negative in VEGF and 5 out of them were positive. Loss of CK20 expression is associated with poorly differentiated carcinoma [11]. Ten (31.3%) out of 31 patients were positive in CK20.
Table 1

Clinicopathological characteristics of CRC patients

Variable

Frequency

Percentile (%)

Sex

  

 Male

16

50.0

 Female

16

50.0

Age at diagnosis (years)

  

 <60

9

28.1

 ≥60

23

71.9

Stage

  

 II

16

50.0

 III

13

40.6

 IV

3

9.4

VEGF

  

 Negative (9)

4

44.44

CK20

  

 +

2

20.0

 ++

4

40.0

 +++

4

40.0

Fold change of 96 selected miRNAs further validated by TaqMan RT-qPCR

To identify miRNAs that are differentially expressed in tissues, we analyzed expression profiles of 1448 miRNAs, founding 497 miRNAs expression profiles showed statistical significance, in which 155 miRNAs have statistical significance in paired t-test and satisfied the strict condition of P ≤ 0.001.

To further validate the expression levels of these miRNAs, 31 patients were qualified and selected for performing qPCR validation phase. In the condition of fold chang >2.0 and P < 0.05, we gained a set of 96 miRNAs that were differentially expressed between the colorectal tissues and normal tissues, which were consistent with the results of TaqMan Human MicroRNA Array. Twelve miRNAs were upexpressed, while 84 miRNAs (has-miR-137, hsa-miR-133a, hsa-miR-143, hsa-miR-363, hsa-miR-4770, hsa-miR-490-5p, hsa-miR-133b, and so on) were deexpressed in tumors compared with those in normal tissues (adjusted P = 0.05) (Figure 1).
Figure 1
Figure 1

Fold change of 96 selected miRNAs further validated by TaqMan RT-qPCR. Twelve miRNAs (hsa-miR-130b, hsa-miR-203, hsa-miR-1974, hsa-miR-592, hsa-miR-200a, hsa-miR-429, hsa-miR-183, hsa-miR-182, hsa-miR-1290, hsa-miR-141, hsa-miR-135b, and hsa-miR-96) were overexpressed, whereas 84 miRNAs (hsa-miR-1, hsa-miR-145, hsa-miR-145*, and so on) were downexpressed in tumor tissues compared with those in normal tissues.

Selected miRNA expression levels in CRC tissues and neighboring noncancerous tissues

After a series of selection processes independently with enter method and conditional forward method in conditional logistic regression, we found nine statistically significant miRNAs in enter method, namely, miR574-3p, miR422a, miR490-3p, miR-374b, miR-133a, let7g, miR-378*, miR-9* and miR-378i.

On the other hand, we found seven statistically significant miRNAs, namely, miR-145, miR-363, miR-378*, miR-137, miR-100, miR-125a-5p, miR-143 in conditional forward method. This result was consistent with Pagliu A. et al.’s study who found that analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression [12]. Besides, the expression levels of these miRNAs between CRC tissues and the neighboring noncancerous colorectal tissues were compared using qRT-PCR analysis. Preliminary results showed that the level of miR874-3p, miR-422a, miR-490-3p, miR-374b, miR-133a, let-7 g, miR-378, miR-9*, and miR-378i were all deregulated in the CRC tissues compared with the neighboring noncancerous colorectal tissues (all P < 0.05) (Figure 2).
Figure 2
Figure 2

Selected miRNA expression levels in CRC tissues and neighboring noncancerous tissues. Selected miRNAs showed statistical significance in conditional logistic regression analysis. (A) has-miR874-3p, miR422a, and miR490-3p expression levels in CRC tissues and neighboring noncancerous colorectal tissues. (B) has-miR374b, has-miR133a, has-let-7 g, has-miR378, has-miR9*, and has-miR378i expression levels in CRC tissues and neighboring noncancerous colorectal tissues.

Logistic regression and fold change of miR-145 in different clinical stages

To further screen the most contribution factors to CRC among these miRNAs, the variables above were used to analyze in the conditional logistic regression. The results indicated that miR-378* is the kept variable with statistical significance to distinguish CRC from normal tissues (P < 0.05; odds ratio = 4.6; 95% CI of odds ratio = 1.25 to 16.84). Similarly,miR145 is also the kept variable with statistical significance to distinguish CRC from normal tissues (P < 0.05; odds ratio = 4.21; 95% CI of odds ratio = 1.17 to 15.13) (Table 2). These results were consistent with those from the study of Zhang et al., who indicated that miRNA378 is a reliable, hemolysis-independent biomarker for CRC [13]. We compared the expression of miR-378* in different clinical stages and found that miR-378* is downregulated in all stages. A previous study also proved that the expression of miR-378a-3p and miR-378a-5p was significantly associated with TNM stage [14]. These results indicate that clinical stage may influence the expression of miRNAs (Figure 3).
Table 2

Conditional logistic regression for the relationship between miRNAs and CRC

Variable

Coefficient

Standard error

Wald

P value

Odds ratio

95% CI

hsa-miR-378*

1.525

0.663

5.297

0.021

4.596

1.25 to 16.84

hsa-miR-145

1.438

0.653

4.853

0.028

4.210

1.17 to 15.13

Figure 3
Figure 3

Fold change of miR-378* and miR-145 in different clinical stages. Expression levels of miR-378* and miR-145 varied in different clinical stages.

Discriminant analysis for miR-378*

To verify the diagnostic value of miR-378*, Fisher discriminant analysis was analyzed to predict the category and determine the diagnostic ability of miR-378*. After ln-gamma transformation of the sample data, the variables followed normal distributions and equal variance matrix for categories I and II.

Evidently, as shown in Table 3, true-positive rate is 80.65% and false-positive rate is 19.35%. The whole discriminant analysis results are listed in Table 3.
Table 3

Discriminant analysis results

Original group

Prediction

Total

Error rate (%)

Tumor

Normal

  

Tumor

25

6

31

19.35

Normal

6

25

31

19.35

Total

31

31

62

19.35

Receiver operator characteristic curve for miR-378* and miR-145

Area under the curve for the receiver operator characteristic function for miR-378* and miR-145 were 0.975 (95% confidence interval 0.923–1.00, p < 0.0005) and 0.996 (95% confidence interval 0.982–1.00, p < 0.0005) separately. At an optimal cut score of ≥3.80 and < −1.975(fold change 0.025) separately, sensitivity was 100% both and specificity was 60% and 98% separately. A score of −1.167 (fold change 0.833) or greater for miR-145 had 93.3% specificity but had sensitivity of only 93.8% (See Figure 4, Table 4).
Figure 4
Figure 4

Receiver operator characteristic curve for miR-378* and miR-145 for the predictor of CRC.miRNA-378* levels had areas under the receiver operator characteristic curve of 97.5% and 99.6% separately.

Table 4

Coordinates of the ROC Curve for miR378* and miR145

miR378*

miR145

Cut-off value

Sensitivity (%)

Specificity (%)

Cut-off value

Sensitivity (%)

Specificity (%)

37.90

100

0.0

−11.084

100

0.0

12.52

100

7.7

−8.427

100

0.1

7.02

100

13.3

−6.117

100

0.1

5.89

100

20.0

−5.166

100

0.2

5.70

100

16.7

−4.489

100

0.3

5.28

100

33.3

−3.919

100

0.3

4.93

100

40.0

−3.717

100

0.4

4.31

100

46.7

−3.390

100

0.5

3.82

100

53.3

−3.063

100

0.5

3.80

100

60.0

−2.864

100

0.6

3.43

93.8

60.0

−2.495

100

0.7

2.39

93.8

66.7

−2.294

100

0.7

1.82

93.8

73.3

−1.975

100

0.8

   

−1.167

93.8

0.9

   

−0.082

93.8

1.0

Discussion

Interestingly, our results in CRC samples agree with those obtained by Faltejskova P et al., who found that the miRNAs functioning as tumor suppressors in CRC are miR-378, miR-375, miR-422a, and miR-215 from 667 miRNAs in a paire design study [15]. Furthermore, Cui SY et al. found that microRNA-145 as a potent tumour suppressor that regulates multiple cellular pathways [16]. Zhang GJ et al. also indicated that miR-378 is an independent prognostic factor that inhibits cell growth and invasion in CRC. Most important is HouY et al. suggest that microRNA-145 as ideal biomarker for the diagnosis of various carcinomas [17].

Notably, our current study showed that discriminant analysis based on expression data revealed that miR-378* can distinguish CRC from normal tissues. This result is important for the potential role of new molecular gene miR-378* in future diagnostic processes in the absence of effective early diagnostic biomarkers.

The different biological effects of any particular miRNA in different cells could be dependent of the cell-specific collection in target genes [18]. miR-378 inhibits progression of human gastric cancer MGC-803 cells by targeting MAPK1 in vitro [19]. miR-378 also promotes BMP2-induced osteogenic differentiation of mesenchymal progenitor cells [20]. Furthermore, miRNA-profiling study proved that miR-378 was significantly upregulated in cachexia related to enhanced adipocyte lipolysis in human cancer [21]. Notably, Panza A, et al., found that miR-145 is a novel target of PPARγ, acting as a tumor suppressor in CRC cell lines and being a key regulator of intestinal cell differentiation by directly targeting SOX9, a marker of undifferentiated progenitors in the colonic crypts [22].

Therefore, high-field miR-378* and miR-145 are powerful means for investigating early CRC signs and are promising sensitive tools to support medical diagnosis. Future validation of these methods is preparing planned on a prospective study. Thus, previous studies reveals that change of miR-378 expression has been previously reported in nasopharyngeal cancer. Yu BL et al. reported that repressing TOB2 expression would cause miR-378 to function as an oncomiR in nasopharyngeal carcinoma [23]; miR-378/ATP also binds Cassette Transporter G1-Signaling pathway [24].

Conclusions

In summary, our real-time PCR results identified alterations of miRNA expression in CRC with two down-regulated miRNAs (miR-378* and miR-145), which may be novel candidate biomarkers for CRC. Although, both miR-145 and miR-378* contribute to the probability of CRC, comparison between the roles of miR-145 and miR-378* in the CRC progression will give more information to the cell transcription mechanisms.

Further mechanistic studies focusing on miR-378* and miR-145 are required to investigate its underlying roles in the tumorigenesis of CRC [24].

Notes

Abbreviations

CRC: 

Colorectal cancer

Real-time RT-PCR: 

Real-time reverse transcription polymerase chain reaction

Declarations

Acknowledgements

The study was supported with the grant no. B2013313, the project of rapid rehabilitation of prospective randomized controlled study of laparoscopic and open colorectal surgery under the concept of operation, financed by Guangdong Province Medical Research Foundation.

We thank all patients and their families for their participation in this trial. We also thank Dr. Zhang for critically reviewing this manuscript.

Authors’ Affiliations

(1)
Guilin Medical College, Guilin, China
(2)
General Hospital of Guangzhou Military Command of PLA, Guangzhou, China

References

  1. Buechner J, Henriksen JR, Haug BH, Tømte E, Flaegstad T, Einvik C. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells. Differentiation. 2011;81(1):25–34.View ArticlePubMedGoogle Scholar
  2. Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006;5:29.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Ma Y, Zhang P, Yang J, Liu Z, Yang Z, Qin H. Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int J Cancer. 2012;130(9):2077–87.View ArticlePubMedGoogle Scholar
  4. Kulwichit W, Nilgate S, Chatsuwan T, Krajiw S, Unhasuta C, Chongthaleong A. Accuracies of Leuconostoc phenotypic identification: a comparison of API systems and conventional phenotypic assays. BMC Infect Dis. 2007;7:69.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Ehli EA, Lengyel-Nelson T, Hudziak JJ, Davies GE. Using a commercially available DNA extraction kit to obtain high quality human genomic DNA suitable for PCR and genotyping from 11-year-old saliva saturated cotton spit wads. BMC Res Notes. 2008;1:133.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Goldschmidt P, Balloy T, Degorge S, Benallaoua D, Batellier L, Koskas F, et al. New ultra rapid test for detection of bacteria. Pathol Biol (Paris). 2011;59(5):248–55.View ArticleGoogle Scholar
  7. Fujimaki S, Funato T, Fujiwara J, Satoh J, Miura T, Kaku M, et al. The construction of a standard RNA synthesized for quantitative RT-PCR system. Rinsho Byori. 2000;48(1):54–9.PubMedGoogle Scholar
  8. Leite KR1, Tomiyama A, Reis ST, Sousa-Canavez JM, Sañudo A, Camara-Lopes LH, et al. MicroRNA expression profiles in the progression of prostate cancer–from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol. 2013;31(6):796–801.View ArticlePubMedGoogle Scholar
  9. Bonney H. An investigation of the use of discriminant analysis for the classification of blade edge type from cut marks made by metal and bamboo blades. Am J Phys Anthropol. 2014;154(4):575–84.View ArticlePubMedGoogle Scholar
  10. Bestas R, Kaplan MA, Isikdogan A. The correlation between serum VEGF levels and known prognostic risk factors in colorectal carcinoma. Hepatogastroenterology. 2014;61(130):267–71.PubMedGoogle Scholar
  11. Kim JH1, Rhee YY, Bae JM, Cho NY, Kang GH. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer. Am J Surg Pathol. 2013;37(10):1532–41.View ArticlePubMedGoogle Scholar
  12. Pagliuca A, Valvo C, Fabrizi E, di Martino S, Biffoni M, Runci D, et al. Analysis of combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. 2012;32(40):4806–13.View ArticlePubMedGoogle Scholar
  13. Zhang GJ, Zhou H, Xiao HX, Li Y, Zhou T. MiR-378 is an independent prognostic factor and inhibits cell growth and invasion in colorectal cancer. BMC Cancer. 2014;14:109.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Li H, Dai S, Zhen T, Shi H, Zhang F, Yang Y, et al. Clinical and biological significance of miR-378a-3p and miR-378a-5p in colorectal cancer. Eur J Cancer. 2014;50(6):1207–21.View ArticlePubMedGoogle Scholar
  15. Christensen LL, Holm A, Rantala J, Kallioniemi O, Rasmussen MH, Ostenfeld MS, et al. Functional Screening Identifies miRNAs Influencing Apoptosis and Proliferation in Colorectal Cancer. PLoS One. 2014;9(6):e96767.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Cui SY, Wang R, Chen LB. MicroRNA-145:a potent tumour suppressor that regulate multiple cellular pathways. J Cell Mol Med. 2014;18(10):1913–26.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Hou Y, Wang X, Chen Y, Mu S. MicroRNA-145 as a ideal bimaker for the diagnosis of various carcinomas. Tumour Biol. 2014;12(10):1010–4283.Google Scholar
  18. Toden S, Okugawa Y, Jascur T, Wodarz D, Komarova NL, Buhrmann C, et al. Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis. 2015;10:1093.Google Scholar
  19. Fei B, Wu H. MiR-378 inhibits progression of human gastric cancer MGC-803 cells by targeting MAPK1 in vitro. Oncol Res. 2012;20(12):557–64.View ArticlePubMedGoogle Scholar
  20. Hupkes M, Sotoca AM, Hendriks JM, van Zoelen EJ, Dechering KJ. MicroRNA miR-378 promotes BMP2-induced osteogenic differentiation of mesenchymal progenitor cells. BMC Mol Biol. 2014;15:1.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Kulyté A, Lorente-Cebrián S, Gao H, Mejhert N, Agustsson T, Arner P, et al. MicroRNA profiling links miR-378 to enhanced adipocyte lipolysis in human cancer cachexia. Am J Physiol Endocrinol Metab. 2014;306(3):E267–74.View ArticlePubMedGoogle Scholar
  22. Panza A. Peroxisome proliferator-activated receptor γ-mediated induction of microRNA−145 opposes tumor phenotype in colorectal cancer. Biochim Biophy Acta. 2014;1843(6):1225–36.View ArticleGoogle Scholar
  23. Yu BL, Peng XH, Zhao FP, Liu X, Lu J, Wang L, et al. MicroRNA-378 functions as an onco-miR in nasopharyngeal carcinoma by repressing TOB2 expression. Int J Oncol. 2014;44(4):1215–22.PubMedGoogle Scholar
  24. Wang D, Yan X, Xia M, Yang Y, Li D, Li X, et al. Coenzyme Q10 Promotes Macrophage Cholesterol Efflux by Regulation of the Activator Protein-1/MicroRNA-378/ATP-Binding Cassette Transporter G1-Signaling Pathway. Arterioscler Thromb Vasc Biol. 2014;12(10):1010–4283.Google Scholar

Copyright

© Peng et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement